curasan AG: Profits Warning for 2010

Online, October 4, 2010 (Newswire.com) - Kleinostheim, Germany - curasan AG, listed in the General Standard (ISIN: DE 000 549 453 8) expects to make a considerable profit instead of the two million euro loss announced for the financial year 2010.

The reason for this is the contract agreement that has just been concluded for the sale of the oncological product Mitem® to the Speciality European Pharma Ltd. (SEP), London, and the extraordinary earnings associated with it. The sale will tentatively come into effect on 1st November.

It has been agreed to maintain silence regarding the value of the transaction.

curasan AG, thus, finalizes the concentration of the product portfolio in the biomaterials sector with the sale of the pharmaceutical drug Mitem®. The liquidity position of the company, which is very good anyway, will improve considerably as a result of this development.